title: [Dermatologic side effects induced by new angiogenesis inhibitors].
abstract: While new anticancer angiogenesis inhibitors present a well-tolerated safety profile, they are not without adverse events. The signaling pathways and/or receptors inhibited by these new drugs are often physiologically expressed in the skin and/or hair follicle and cutaneous toxicity is on the forefront. This article reviews the main dermatologic adverse events induced by these targeted anticancer therapies with a partial or exclusive antiangiogenic activity: sorafenib, sunitinib, pazopanib, vandetanib, everolimus, temsirolimus or bevacizumab.
authors: Institut Claudius-Regaud, Toulouse cedex, France. sibaud.vincent@claudiusregaud.fr
authors: Vincent
authors: V
authors: Sibaud
authors: Ignacio
authors: I
authors: Garrido-Stowhas
authors: Ewa
authors: E
authors: Cottura
authors: Christine
authors: C
authors: Chevreau
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D001557:Benzenesulfonates / Q000009:adverse effects; D000068258:Bevacizumab; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D007191:Indazoles; D007211:Indoles / Q000009:adverse effects; D058990:Molecular Targeted Therapy / Q000009:adverse effects / Q000379:methods; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010880:Piperidines / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D011743:Pyrimidines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D011799:Quinazolines / Q000009:adverse effects; D012867:Skin / Q000187:drug effects*; D000077157:Sorafenib; D013449:Sulfonamides / Q000009:adverse effects; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D007191:Indazoles; D007211:Indoles; D010671:Phenylurea Compounds; D010880:Piperidines; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; D011799:Quinazolines; D013449:Sulfonamides; D009536:Niacinamide; D000068258:Bevacizumab; C516667:pazopanib; D000077157:Sorafenib; D000077210:Sunitinib; C452423:vandetanib